ReviewFrontiers in microbiology2026
Gut microbiota and metabolites as potential modulators of cognitive impairment after aneurysmal subarachnoid hemorrhage: a hypothesis-driven review.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment is a major sequela following aneurysmal subarachnoid hemorrhage (aSAH), severely influencing patients' long-term quality of life. Its mechanism of occurrence is complex and has not been fully clarified to date. In recent years, the role of the gut microbiota in neurological diseases has gradually been revealed, providing a compelling theoretical framework for exploring the gut-brain axis in aSAH-induced cognitive impairment. Recognizing the limitations of current cross-sectional evidence, this review explicitly aims to propose testable hypotheses rather than establish definitive causation. In this study, we propose the novel "gut-derived secondary hit" hypothesis, aiming to explore how secondary gut microbiota dysbiosis, triggered by primary central nervous system injury following aSAH, may act as a potential modulator contributing to long-term cognitive impairment through altered shifts in the metabolite profile. In this review, we outline the clinical manifestations and pathological mechanisms of aSAH-induced cognitive impairment, as well as the observed shifts in gut microbial composition. We further deeply explore the complex pathways through which the gut microbiome and its derived metabolites may be associated with cognitive impairment. In addition, incorporating recent advances, we discuss prospective microbiome-targeted therapeutic strategies, providing a translational perspective for future mechanistic studies and the clinical prevention and treatment of aSAH-induced cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.